About hookipa pharma inc. - HOOK
HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. It also focuses on immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company was founded by Rolf M. Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel D. Pinschewer in 2011 and is headquartered in New York, NY.
HOOK At a Glance
HOOKIPA Pharma, Inc.
350 Fifth Avenue
New York, New York 10118
| Phone | 43-1-890-6360 | Revenue | 9.70M | |
| Industry | Biotechnology | Net Income | -13,837,000.00 | |
| Sector | Health Technology | Employees | 10 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
HOOK Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.164 |
| Price to Book Ratio | 0.34 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.724 |
| Enterprise Value to Sales | -2.679 |
| Total Debt to Enterprise Value | -0.005 |
HOOK Efficiency
| Revenue/Employee | 970,100.00 |
| Income Per Employee | -1,383,700.00 |
| Receivables Turnover | 4.37 |
| Total Asset Turnover | 0.156 |
HOOK Liquidity
| Current Ratio | 6.346 |
| Quick Ratio | 6.346 |
| Cash Ratio | 5.692 |
HOOK Profitability
| Gross Margin | 92.97 |
| Operating Margin | -376.992 |
| Pretax Margin | -142.624 |
| Net Margin | -142.635 |
| Return on Assets | -22.245 |
| Return on Equity | -33.05 |
| Return on Total Capital | -42.372 |
| Return on Invested Capital | -32.923 |
HOOK Capital Structure
| Total Debt to Total Equity | 0.415 |
| Total Debt to Total Capital | 0.413 |
| Total Debt to Total Assets | 0.323 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |